Interestingly, it was reported that treatment of Cognitive impairment associated with Alzheimer’s disease (AD) and schizophrenia was associated with α7 nicotinic acetylcholine receptor (α7nAChR) that represented promising therapeutic candidates [190]. Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.